NCT03588039: Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03588039
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase; Patients must have previously progressed on or become intolerant of at least 1 line of systemic chemotherapy for metastatic or advanced disease
Exclusions: 
https://ClinicalTrials.gov/show/NCT03588039

Comments are closed.

Up ↑